What’s fuelling South Korea’s mycobacterium diagnostic tests market?

The country accounts for 8% of this year's APAC mycobacterium tuberculosis tests sector.

The rising incidence of tuberculosis (TB) and developments in molecular diagnostics are driving South Korea’s mycobacterium diagnostic tests market, projected to expand at a compound annual growth rate of 3% until 2034.

A report by GlobalData revealed that South Korea accounts for approximately 8% of this year's Asia Pacific mycobacterium tuberculosis tests market.

“Technological advancements in molecular diagnostics that enable faster and more precise detection of resistant TB strains are crucial to curb the spread of XDR-TB and improve patient outcomes,” said Jyoti Sharma, Medical Devices Analyst at GlobalData.

In a recent development, South Korea’s SD Biosensor, Inc. partnered with Japan’s Research Institute of Tuberculosis under the Japan Anti-Tuberculosis Association and South Korea’s International Tuberculosis Research Centre.

Through a tripartite memorandum of understanding, the partners will focus on developing advanced molecular diagnostic solutions for extensively drug-resistant tuberculosis.

“Such innovations and collaborations are critical in addressing the challenges posed by drug-resistant TB,” Sharma added.